Vidac Pharma Holding Plc to hold Annual Shareholders Meeting Sept 29th, 2023
London (UK), Rehovot (IL), 13th September 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
Vidac Pharma Holding Plc will hold its Annual Shareholders Meeting in person and on-line on Sept 29th at 10am CET and present the Balance Sheet for approval and decide on giving authority to the Board to issu...
Vidac Pharma announces international experts’ participation to its “Toposteric” Round Table at HTID5 in Paris Oct 24-25, 2023
London (UK), Rehovot (IL), Paris (FR) August 30h, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
Under the Organization of Dr Alain Herrera previously head of the Oncology Franchise at Sanofi around the new paradigm for drug discovery proposed by Vidac Pharma, the Company is happy to announce it...
Vidac Pharma announces signature of a Research Collaboration and License Agreement with Sheba Hospital Tel Hashomer
London (UK), Rehovot (Israel) Tel Hashomer (Israel) August, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
Vidac Pharma announces a Research Collaboration and License Agreement with Sheba Medical Center on modification of Tumor microenvironment (TME) induced by its New Chemical Entities in order to...
Vidac Pharma Holding cooperation with Centroderm Gmbh for its next Clinical Trial in Actinic Keratosis
London (UK), Rehovot (Israel) Wuppertal (Germany) August 15th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
Vidac Pharma is proud to announce that its next pre-Phase 3 Clinical trial on advanced Actinic Keratosis will be held in close collaboration with Centroderm Gmbh headed by Prof. Thomas Dirs...
Vidac Pharma Holding Plc. to be in a dual listing in Hamburg and Stuttgart stock Exchanges.
London (UK), Rehovot (Israel) August 11th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
London August 11. Vidac Pharma Holding Plc announced that from today August 11, its shares will be dual listed simultaneously on both the Hamburg and the Stuttgart stock
exchange to facilitate trading.
Stuttgart...
VIDAC PHARMA HOLDING Plc Shareholder Unanimous Vote for Capital Increase delegated to its Board
London (UK), Rehovot (Israel) August 10th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
London UK. The extraordinary meeting of Shareholders which took place on August 8th in person and digitally with more than 90% participation voted unanimously to delegate to the Board the power of creating 1...
Vidac Pharma to hold Extraordinary Shareholder Meeting to prepare for potential investments
London (UK), Rehovot (Israel) July 26th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
Vidac Pharma to hold Extraordinary Shareholder Meeting to prepare for potential investments.
Vidac Pharma Holding invited a Share Holders Meeting to be held in person and digitally on August 8, 2023 in order to cr...
Vidac Pharma and HCS Pharma Announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma anti Solid Tumors drug candidates
London (UK), Rehovot (Israel) Lille (France) July 17th , 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).
www.vidacpharma.com
Poor predictability of animal models is one of the most time and money consuming step in pre-clinical development of Anti-Cancer Drugs before the Clinical Phases. Vidac Pharma chose to use the 3D “...
Vidac Pharma invited to organize Round Table on its Toposteric Paradigm at main European Health Tech Conference
Vidac Pharma invited to organize Round Table on its Toposteric Paradigm at main
European Health Tech Conference
London (UK) and Rehovot (Israel) July 10th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).
www.vidacpharma.com
Vidac Pharma was invited to organize a Round Table discussion on its new paradigm for Drug Discovery...
Vidac Pharma announces positive preliminary results of its Phase 2A in CTCL
London (UK) and Rehovot (Israel) June 27th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).
www.vidacpharma.com
The preliminary results on more than 50% of the planned number of patients in this rare disease shows a more than 50% overall response and more than 20% Complete Clearance in Cutaneous T Cell Lymphoma patients...
Vidac Pharma invited to organize Round Table on its Toposteric Paradigm at main European Health Tech Conference
London (UK) and Rehovot (Israel) July 5th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).
www.vidacpharma.com
Vidac Pharma was invited to organize a Round Table discussion on its new paradigm for Drug Discovery: the “Toposteric effect” at the Health Tech Innovation Days conference in Paris, October 24-25, 2023.
The...
Vidac Pharma will participate to the HTID5 as a fully sponsored guest speak
London (UK) and Rehovot (Israel) June 16th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com)
As one of three laureate of the Prize for Innovation it received during the Paris HealthTech Innovation Days HTID-4 in October 2022, Vidac Pharma will participate as a fully sponsored guest to the HTID-5 a c...
Vidac Pharma Holding Plc. Nomination of new Board and Scientific Advisory committee and update.
London (UK) and Rehovot (Israel) April 26, 2023
Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com)
In preparation for its new status as a public company registered in the Hamburg stock Exchange (T9G, WKN: A3DTUQ, ISIN:GB00BM9XQ619), Vidac Pharma Holding (The Company) is expanding its company board: Mr. Jo...
Expiration of the G.E.M Share Purchase Facility
London (UK) and Rehovot (Israel) April 24, 2023
Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com)
Vidac Pharma Holding Plc. Informs of automatic expiration of a share purchase facility agreement with General Emerging Market (G.E.M) as for April 13th, 2023. As financial Planning of the company did not inc...
VIDAC PHARMA HOLDING PLC SHARES ARE ADMITTED FOR TRADING BY HAMBURG STOCK EXCHANGE
London (UK) and Rehovot (Israel). VIDAC PHARMA HOLDING PLC (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com) is happy to announce a listing of company shares in the Hamburg Stock Exchange.
Vidac Pharma is a clinical stage company exploiting a new paradigm in Anti-Cancer Drug Discovery by dissociating the enzymatic complex which ca...
Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis
Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development company, today announced the filing of an Investigational New Drug (IND) application with the U.S. FDA for VDA-1102 topical skin ointment, its highly selective, proprietary VDAC/HK2 modulator for the treatment of actinic keratosis (AK), an early form of cutaneous...
Old Press Releases
Vidac Pharma Appoints Dr. Paul Salama as Vice President of Chemistry, Manufacturing, and Control
Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Dr. Paul Salama as its vice president of chemistry, manufacturing, and control (CMC). Dr. Salama brings to Vidac more than 20 years of experience in medicinal chemistry, formulation, GMP process chemistry and manufacturin...
Vidac Pharma Appoints Dr. Chaim Brickman as Vice President of Clinical Affairs
Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Chaim M. Brickman, M.D. as its vice president of clinical affairs. Chaim will oversee all clinical development activities for the company, as Vidac rapidly advances its product candidates in human clinical trials for a r...
Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator
Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development company, today announced the initiation of Phase I first-in-human studies with VDA-1102 ointment, its highly selective, proprietary VDAC/HK2 modulator for the treatment of actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC).
As a se...
Vidac Pharma Completes $9 Million Series A Financing I Advances Phase 2 Studies with VDA-1102 In Actinic Keratosis
Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer and oncodermatology disease, announced today that it has closed a $9 million a Series A financing round. The financing was led by a new investor, Israel Biotech Fund. Existi...
VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS
Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced the appointment of Dr. Chaim Brickman as the company's Chief Medical Officer, and the appointment of Dr. Vered Behar as the company's Chief Science Officer. Dr. Brickman was formerly Vidac's Vice President of Medical Affairs...
VIDAC PHARMA PHASE 2A STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION
Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced that the ongoing Phase 2 study with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, in actinic keratosis (AK) met a pre-determined interim analysis criterion. The drug candidate is being developed by Vidac as a fi...
Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has initiated a Phase 2 trial with VDA-1102 ointment, a potent selective VDAC/HK2 modulator, to treat subjects with actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC). The drug...
VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT
Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has completed a Phase 1a trial of VDA-1102 ointment, a topical ointment formulation of VDA-1102, a potent selective VDAC/HK2 modulator, for the treatment of actinic keratosis (AK) and other hyperproliferative d...
VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS
Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102 OINTMENT in Actinic Keratosis
- Establishes that VDA-1102 ointment is well-tolerated, non-irritating and safe
- Demonstrates reduction of number of actinic keratosis lesions in treatment field
Jerusalem, Israel, October 12, 2017 – Vidac Pharma, a clinical-...
VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM
Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will participate as Company Spotlight presenter at the 4th Annual Dermatology Innovation Forum. The company presentation will be on Thursday, February 15, 2018 at 2:40 pm PT at the Manchester Grand...
VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE
Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and dermatology-focused biopharmaceutical company, today announced that Oren M. Becker, PhD, President and Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:00 pm EST at the Marriott Marquis in New York City...
VIDAC PHARMA TO PRESENT AN IMMUNO-METABOLISM POSTER AT THE 2018 AACR ANNUAL MEETING 2018
Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present an immono-metabolism poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The poster entitled: "A Bi-functional Mechanism of Action: Activating the NLRP3 Inflammasome in Macrophag...
VIDAC PHARMA TO PRESENT A POSTER AT THE EACR25 2018 MEETING
Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the 25th Biennial Congress of the European Association for Cancer Research (EACR25) in Amsterd...
VIDAC PHARMA ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS
Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early stage of cutaneous squamous cell carcinoma (cSCC), which is a common form of non-melanoma skin...
VIDAC PHARMA TO PRESENT A POSTER AT THE SITC 2018 MEETING
Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach for Simultaneous Targeting of t...
VIDAC PHARMA ANNOUNCES PUBLICATION OF A PEER REVIEWED ARTICLE ON VDA-1102 MECHANISM OF ACTION
Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643), discussing the discovery of Vidac’s anti-cancer drug VDA-1102 and its pre-clinical characteriz...
VIDAC PHARMA ANNOUNCES INCLUSION OF THE FIRST PATIENT IN A PLACEBO CONTROLLED PHASE II STUDY
Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneous T-Cell Lymphoma treated with its first in class drug VDA 1102 . VDA 1102 disrupt the binding of the glycolytic enzyme HK2 over expressed in Cancer Cells from the VDAC channel. This causes...
Vidac Pharma Secures EUR 20m Capital Commitment From GEM
NESS-ZIONA, Israel, April 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment.
Under the agreement, GEM commits to prov...
Vidac Pharma Ltd.: New Chemical Entities Patent Granted
Rehovot, Israel Sept 13, 2021
Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use such as IV, IM and/or Per-Os use. “This is opening the way to explore possible treatment o...
VIDAC PHARMA LTD ANNOUNCES WIDER SPECTRUM AUTHORIZATION OF ITS CTCL PHASE 2 CLINICAL TRIAL.
Rehovot, Israel Sept 20, 2021
Based of the satisfactory safety data of VIDAC VDA 1102 on selected patients, Vidac Pharma received authorization to widen the scope of the trial to CTCL whole spectrum of conditions.
“We are very satisfied with the results of the first step which on top of the safety results granted to our trial a dose ranging proto...